|

The Application of Serum DNA Methylation for Patients With HCC

RECRUITINGN/ASponsored by Chiayi Christian Hospital
Actively Recruiting
PhaseN/A
SponsorChiayi Christian Hospital
Started2023-03-28
Est. completion2025-03-31
Eligibility
Age20 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05764551

Summary

The goal of this single-arm prospective study is to evaluate the application of serum DNA methylation for HCC patients with normal alpha-fetoprotein. The main question it aims to answer is . Is the dynamic change of serum DNA methylation correlated to recurrence or treatment response of HCC

Eligibility

Age: 20 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 20 years old
* The diagnosis of hepatocellular carcinoma (HCC) according to AASLD 2018 clinical guidelines or histology report
* Individuals with HCC and normal serum alpha-fetorpotein level (\<20 ng/ml)
* Individuals who could sign informed consent

Exclusion Criteria:

* The histology report revealed non-HCC, HCC mixed with cholangiocarcinoma or sarcomatoid HCC
* Individuals with HCC and other concurrent malignancies
* Individuals with chronic kidney disease who could not tolerate contrast-enhanced dynamic images
* Individuals ever receiving any organ transplantation
* Individuals with HIV infection
* Individuals who could not able to understand and sign informed consent

Conditions4

CancerHepatocellular CarcinomaLiver CancerLiver Disease

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.